Home › Funds › RTW INVESTMENTS, LP › VRDN
RTW INVESTMENTS, LP position in VRDN
VIRIDIAN THERAPEUTICS INC · Health Care
RTW INVESTMENTS, LP reported holding 4,977,832 shares of VRDN (VIRIDIAN THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$102.0M, representing 1.03% of its reported portfolio and ranking #36 among its reported holdings. RTW INVESTMENTS, LP has disclosed VRDN holdings in 4 of the last 12 reported quarters, going back to Q4 2023.
Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR
How RTW INVESTMENTS, LP's VRDN position evolved
RTW INVESTMENTS, LP first disclosed a stake in VRDN in Q4 2023 at 605,816 shares (US$13.2M). The position peaked in Q3 2026 at 4,977,832 shares, worth US$102.0M. Across 4 filings, RTW INVESTMENTS, LP held the position steady without any share-count change. The most recent filing (Q3 2026) shows 4,977,832 shares valued at US$102.0M.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2023 | 605.82K | $13.19M | New |
| Q1 2024 | 605.82K | $10.61M | Hold |
| Q2 2024 | 605.82K | $7.88M | Hold |
| Q3 2026 | 4.98M | $102.03M | New |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About VRDN and 13F data
VRDN (VIRIDIAN THERAPEUTICS INC) is a Health Care company. 42 other funds we track also report a position in VRDN — the largest reported positions include Paradigm Biocapital Advisors LP (US$227.1M), Kynam Capital Management, LP (US$126.6M), Bellevue Group AG (US$123.7M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding VRDN
- Paradigm Biocapital Advisors LP 12.41M sh · $227.08M · Q3 2026
- Kynam Capital Management, LP 6.15M sh · $126.59M · Q3 2026
- Bellevue Group AG 6.73M sh · $123.67M · Q2 2026
- Fairmount Funds Management LLC 5.09M sh · $93.52M · Q2 2026
- Deep Track Capital, LP 3.83M sh · $64.34M · Q3 2026
- Atlas Venture Life Science Advisors, LLC 4.50M sh · $61.83M · Q3 2026
- Venrock Adviser, LLC 3.26M sh · $59.85M · Q2 2026
- Context Capital Management, LLC 49.00M sh · $56.47M · Q3 2026
- Avoro Capital Advisors LLC 2.50M sh · $51.48M · Q3 2026
- BAKER BROS. ADVISORS LP 2.38M sh · $43.78M · Q2 2026
- Caligan Partners LP 2.19M sh · $40.30M · Q2 2026
- Novo Holdings A/S 2.13M sh · $39.22M · Q2 2026
More on RTW INVESTMENTS, LP
FAQ
How long has RTW INVESTMENTS, LP held VRDN?
RTW INVESTMENTS, LP has disclosed VRDN holdings in 4 of the last 12 reported quarters, going back to Q4 2023.
What is RTW INVESTMENTS, LP's current position in VRDN?
As of Q3 2026, RTW INVESTMENTS, LP holds 4.98M shares of VRDN (VIRIDIAN THERAPEUTICS INC), valued at $102.03M, representing 1.03% of its reported portfolio and ranking #36.
Has RTW INVESTMENTS, LP been buying or selling VRDN?
In the latest 13F filing (Q3 2026), RTW INVESTMENTS, LP newly opened its position in VRDN. The position peaked in Q3 2026 at 4.98M shares.
Which other funds hold VRDN?
Other major institutional holders of VRDN include Paradigm Biocapital Advisors LP, Kynam Capital Management, LP, Bellevue Group AG, among 42 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.